ABOS logo

ABOS Acumen Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$0.19
-0.01 (-3.52%)

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Ph…

Market Cap: $13.49Macumenpharm.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
2 mentions
—
60d
50
4 mentions
—
90d
50
8 mentions
—
news: 8

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 1Sell 0Strong Sell 0
Avg price target$7+3653.4%
Low $7Median $7High $7
Current Consensus

Revenue

$0.00-100.00%
$0.00$243.3K$486.7K$730.0K
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-2.05
$-2.16–$-1.88
3 analysts
FY2026
$-1.54
$-1.65–$-1.41
3 analysts
FY2027
$-0.75
$-0.85–$-0.65
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Daniel J. O'Connell
Sector
Healthcare
Industry
Biotechnology
Employees
61
Beta
0.33
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-11.72
acumenpharm.com